JPH08500104A - 結晶質アミホスチン組成物及びその調製方法並びに使用 - Google Patents
結晶質アミホスチン組成物及びその調製方法並びに使用Info
- Publication number
- JPH08500104A JPH08500104A JP6505479A JP50547994A JPH08500104A JP H08500104 A JPH08500104 A JP H08500104A JP 6505479 A JP6505479 A JP 6505479A JP 50547994 A JP50547994 A JP 50547994A JP H08500104 A JPH08500104 A JP H08500104A
- Authority
- JP
- Japan
- Prior art keywords
- amifostine
- composition
- crystalline
- temperature
- vacuum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960001097 amifostine Drugs 0.000 title claims abstract description 185
- 239000000203 mixture Substances 0.000 title claims abstract description 115
- 238000000034 method Methods 0.000 title claims description 67
- 238000002360 preparation method Methods 0.000 title abstract description 19
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 title abstract 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 22
- 239000007787 solid Substances 0.000 claims abstract description 13
- TXQPXJKRNHJWAX-UHFFFAOYSA-N 2-(3-aminopropylamino)ethylsulfanylphosphonic acid;trihydrate Chemical compound O.O.O.NCCCNCCSP(O)(O)=O TXQPXJKRNHJWAX-UHFFFAOYSA-N 0.000 claims description 182
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 158
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 70
- 239000000243 solution Substances 0.000 claims description 45
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 23
- 229940126534 drug product Drugs 0.000 claims description 21
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 21
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 18
- 239000013078 crystal Substances 0.000 claims description 17
- 235000010355 mannitol Nutrition 0.000 claims description 17
- 229930195725 Mannitol Natural products 0.000 claims description 15
- 239000000594 mannitol Substances 0.000 claims description 15
- 238000001556 precipitation Methods 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 15
- 238000001291 vacuum drying Methods 0.000 claims description 14
- 238000001816 cooling Methods 0.000 claims description 13
- 230000004224 protection Effects 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 230000005496 eutectics Effects 0.000 claims description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 230000005855 radiation Effects 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 238000000137 annealing Methods 0.000 claims description 5
- 238000002425 crystallisation Methods 0.000 claims description 5
- 230000008025 crystallization Effects 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 150000004684 trihydrates Chemical class 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 239000008215 water for injection Substances 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims 2
- 239000011261 inert gas Substances 0.000 claims 2
- 238000010792 warming Methods 0.000 claims 2
- 229910052786 argon Inorganic materials 0.000 claims 1
- 230000001767 chemoprotection Effects 0.000 claims 1
- 239000002178 crystalline material Substances 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 239000001307 helium Substances 0.000 claims 1
- 229910052734 helium Inorganic materials 0.000 claims 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 239000008186 active pharmaceutical agent Substances 0.000 description 21
- 229940088679 drug related substance Drugs 0.000 description 20
- 239000000523 sample Substances 0.000 description 16
- -1 3-aminopropylamino Chemical group 0.000 description 15
- 238000001035 drying Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 238000005259 measurement Methods 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 7
- YHPLKWQJMAYFCN-UHFFFAOYSA-N WR-1065 Chemical compound NCCCNCCS YHPLKWQJMAYFCN-UHFFFAOYSA-N 0.000 description 6
- 239000008247 solid mixture Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- 238000013480 data collection Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- NXIUFVXDTRMRKG-UHFFFAOYSA-M diethoxy-sulfanylidene-tricyclohexylstannylsulfanyl-lambda5-phosphane Chemical compound C1CCCCC1[Sn](C1CCCCC1)(SP(=S)(OCC)OCC)C1CCCCC1 NXIUFVXDTRMRKG-UHFFFAOYSA-M 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 150000003573 thiols Chemical class 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-M hydron;thiophosphate Chemical compound OP(O)([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-M 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000013112 stability test Methods 0.000 description 4
- 239000012086 standard solution Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- HRQDCDQDOPSGBR-UHFFFAOYSA-M sodium;octane-1-sulfonate Chemical compound [Na+].CCCCCCCCS([O-])(=O)=O HRQDCDQDOPSGBR-UHFFFAOYSA-M 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical compound OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- OJZGWRZUOHSWMB-UHFFFAOYSA-N ethoxy-dihydroxy-sulfanylidene-$l^{5}-phosphane Chemical compound CCOP(O)(O)=S OJZGWRZUOHSWMB-UHFFFAOYSA-N 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 210000000569 greater omentum Anatomy 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- JYVLIDXNZAXMDK-UHFFFAOYSA-N pentan-2-ol Chemical compound CCCC(C)O JYVLIDXNZAXMDK-UHFFFAOYSA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- HJHVQCXHVMGZNC-JCJNLNMISA-M sodium;(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoate Chemical compound [Na+].O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C HJHVQCXHVMGZNC-JCJNLNMISA-M 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
- WSKJXBGBFPSACA-UHFFFAOYSA-N 1-(2-aminoethylamino)ethylsulfanylphosphonic acid Chemical compound OP(=O)(O)SC(C)NCCN WSKJXBGBFPSACA-UHFFFAOYSA-N 0.000 description 1
- 229940015297 1-octanesulfonic acid Drugs 0.000 description 1
- SCLGGNBFBLJQFU-UHFFFAOYSA-N 3-aminopropyl acetate Chemical compound CC(=O)OCCCN SCLGGNBFBLJQFU-UHFFFAOYSA-N 0.000 description 1
- XDRLRDHLCIFZIW-UHFFFAOYSA-N 3-azaniumylpropyl(2-sulfanylethyl)azanium;dichloride Chemical compound Cl.Cl.NCCCNCCS XDRLRDHLCIFZIW-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 240000002989 Euphorbia neriifolia Species 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 101150097381 Mtor gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- CVBNMWXECPZOLM-UHFFFAOYSA-N Rhamnetin Natural products COc1cc(O)c2C(=O)C(=C(Oc2c1)c3ccc(O)c(O)c3O)O CVBNMWXECPZOLM-UHFFFAOYSA-N 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- BIQVLUUDYJRKIR-UHFFFAOYSA-N [2-(3-aminopropylamino)-2-methylpropyl]sulfanylphosphonic acid Chemical compound OP(=O)(O)SCC(C)(C)NCCCN BIQVLUUDYJRKIR-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- KKYDPAJEXLEYEY-UHFFFAOYSA-N ethanethiol dihydrochloride Chemical compound Cl.Cl.CCS KKYDPAJEXLEYEY-UHFFFAOYSA-N 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- WUOSYUHCXLQPQJ-UHFFFAOYSA-N n-(3-chlorophenyl)-n-methylacetamide Chemical class CC(=O)N(C)C1=CC=CC(Cl)=C1 WUOSYUHCXLQPQJ-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 229910052760 oxygen Chemical group 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000000718 radiation-protective agent Substances 0.000 description 1
- 230000003537 radioprotector Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000012496 stress study Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titanium dioxide Inorganic materials O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000011123 type I (borosilicate glass) Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
- C07F9/165—Esters of thiophosphoric acids
- C07F9/1651—Esters of thiophosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Organic Insulating Materials (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Sub-Exchange Stations And Push- Button Telephones (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.結晶質アミホスチン組成物の調製方法であって、 (a)アミホスチン、エタノールおよび水を含有する組成物を調製し、その際 、アミホスチンとエタノールと水の相対量は、室温付近から約10℃までの温度 では粒子不含の溶液が得られるが、0℃以下に冷却するとアミホスチンの結晶質 沈殿が生じるようなものであり、 (b)結晶質アミホスチンの沈殿を生じさせるのに十分な時間にわたり0℃以 下の温度に該組成物を冷却し、そして (c)得られた混合物を真空乾燥して、安定性が向上した固体の結晶質アミホ スチン組成物を残存させる、各段階からなる方法。 2.段階(c)の真空乾燥の完了後に、前記組成物に無菌の不活性ガスを導入す ることをさらに含む、請求項1に記載の方法。 3.前記不活性ガスがアルゴン、窒素およびヘリウムよりなる群から選ばれる、 請求項2に記載の方法。 4.段階(b)の温度が前記組成物の共融点付近である、請求項1に記載の方法 。 5.段階(b)の後で、得られた混合物の温度を、前記の共融温度より約1〜2 0℃高いアニール温度まで上げ、その後段階(c)を行う前に該混合物の温度を アニール温度から共融温度またはそれ以下に冷却することをさらに含む、請求項 4に記載の方法。 6.前記の共融温度が約0℃〜約−80℃の範囲である、請求項4に記載の方法 。 7.前記のアニール温度が約−30℃〜約10℃の範囲であり、前記の共融温度 が約0℃〜約−80℃の範囲である、請求項5に記載の方法。 8.前記組成物が組成物1mlあたり約50〜400mgのアミホスチン、約1〜 35%(v/v)のエタノール、および約65〜99%(v/v)の水を含有する、請求項 1に記載の方法。 9.前記組成物が組成物1mlあたり約125〜250mgのアミホスチン、約5 〜20%(v/v)のエタノール、および約80〜95%(v/v)の水を含有する、請求 項1に記載の方法。 10.前記組成物が組成物1mlあたり約100mgのアミホスチン、約10%(v/v )のエタノール、および約90%(v/v)の水を含有する、請求項1に記載の方法。 11.段階(b)の前記温度が約−5℃〜約−40℃の範囲である、請求項1に記 載の方法。 12.段階(b)の前記温度が約−20℃である、請求項1に記載の方法。 13.滅菌段階をさらに含む、請求項1、4または5に記載の方法。 14.前記の滅菌段階が冷却に先立って段階(a)の前記組成物を滅菌 濾過することからなる、請求項13に記載の方法。 15.前記の結晶質アミホスチンがアミホスチンの水和物である、請求項1、4、 5または14に記載の方法。 16.前記の結晶質アミホスチンがアミホスチン三水和物である、請求項1、4、 5または14に記載の方法。 17.前記の結晶質アミホスチンが約1〜3モルの結晶水を含む、請求項1、4、 5または14に記載の方法。 18.前記組成物が製剤学的に許容される賦形剤をさらに含有する、請求項1、4 、5または14に記載の方法。 19.前記賦形剤が塩化ナトリウム、グリシン、ブドウ糖、ショ糖、およびマンニ トールよりなる群から選ばれる、請求項18に記載の方法。 20.前記賦形剤がマンニトールである、請求項18に記載の方法。 21.結晶質アミホスチン組成物の調製方法であって、 (a)室温付近から約10℃までの温度では粒子不含の溶液が得られるが、0 ℃以下に冷却するとアミホスチンの結晶質沈殿が生じるように、組成物1mlあた り約50〜300mgのアミホスチン、約3〜30%(v/v)のエタノール、約7 0〜97%(v/v)の水、任意に、組成物1mlあたり約5〜300mgの製剤学的 に許容される賦形剤を含有する組成物を調製し、 (b)結晶質アミホスチンの沈殿を生じさせるのに十分な時間にわたり約−5 ℃〜約−40℃の範囲内の温度に該組成物を冷却し、そして (c)得られた混合物を真空乾燥して、安定性が向上した固体の結晶質アミホ スチン組成物を残存させる、各段階からなる方法。 22.段階(a)の後で段階(c)の前に行う段階を約0.5〜72時間にわたっ て実施する、請求項1、4、5または21に記載の方法。 23.段階(a)の後で段階(c)の前に行う段階を約2〜24時間にわたって実 施する、請求項1、4、5または21に記載の方法。 24.段階(c)を約1〜72時間にわたって実施する、請求項1、4、5または 21に記載の方法。 25.段階(c)を約10〜20時間にわたって実施する、請求項1、4、5また は21に記載の方法。 26.段階(c)を約10〜1000mTorrの真空下で実施する、請求項1、4、 5または21に記載の方法。 27.段階(c)を約150mTorrの真空下で実施する、請求項1、4、5または2 1に記載の方法。 28.請求項1、4、5、13、18または21の方法により調製された、安定性が向上 した結晶質アミホスチン組成物。 29.放射線防護または化学防護を必要とする被験者に、製剤学的に許容されるビ ヒクルを用いて再調製された、有効量の請求項28の結晶質アミホスチン組成物を 投与することからなる、放射線防護または化学防護を必要とする被験者の処置方 法。 30.前記の再調製された医薬組成物を非経口的に投与する、請求項29に記載の方 法。 31.前記の再調製された医薬組成物を静脈内、筋肉内、皮下、空洞内、または鞘 内に投与する、請求項29に記載の方法。 32.製剤学的に許容されるビヒクルを用いて注射可能な粒子不含の薬剤生成物に 再調製し得る、真空乾燥した結晶質アミホスチンを 含有する、安定性の向上した無菌組成物。 33.製剤学上の賦形剤をさらに含有する、請求項32に記載の無菌組成物。 34.前記賦形剤が塩化ナトリウム、グリシン、ブドウ糖、ショ糖、およびマンニ トールよりなる群から選ばれる、請求項33に記載の無菌組成物。 35.前記ビヒクルが注射用の水(USP)または生理食塩水である、 請求項32に記載の無菌組成物。 36.前記の結晶質アミホスチンがアミホスチンの水和物である、請求項32に記載 の無菌組成物。 37.前記の結晶質アミホスチンがアミホスチン三水和物である、請求項32に記載 の無菌組成物。 38.前記の結晶質アミホスチンが約1〜3モルの結晶水を含む、請求項32に記載 の無菌組成物。 39.約10〜10,000mgの真空乾燥した結晶質アミホスチン、および、任 意に約10〜10,000mgの製剤学的に許容される賦形剤を含有する、安定 性の向上した真空乾燥した結晶質アミホスチンの無菌の単回投与量組成物であっ て、製剤学的に許容されるビヒクルを用いて注射可能な粒子不含の薬剤生成物に 再調製することができる組成物。 40.約100〜1000mgの真空乾燥した結晶質アミホスチンおよび約100 〜1000mgのマンニトールを含有する、請求項39に記載の無菌の単回投与量 組成物。 41.約500mgの真空乾燥した結晶質アミホスチンおよび約500mgのマン ニトールを含有する、請求項39に記載の無菌の単回投与量組成物。 42.放射線防護または化学防護を必要とする被験者に、再調製された有効量の請 求項32または33の無菌組成物を投与することからなる、放射線防護または化学防 護を必要とする被験者の処置方法。 43.放射線防護または化学防護を必要とする被験者に、再調製された有効量の請 求項39または40の単回投与量組成物を投与することからなる、放射線防護または 化学防護を必要とする被験者の処置 方法。 44.安定性が向上した真空乾燥アミホスチン。 45.前記アミホスチンが三水和物である、請求項44に記載の真空乾燥アミホスチ ン。 46.前記アミホスチンが結晶質である、請求項44に記載の真空乾燥アミホスチン 。 47.前記アミホスチンが三水和物である、請求項46に記載の真空乾燥アミホスチ ン。 48.実施例9に記載した結晶構造を実質的に有する結晶質アミホスチン三水和物 。 49.結晶質アミホスチン組成物の調製方法であって、 (a)室温付近の温度で粒子不含の溶液が得られるように、組成物1mlあたり 約100mgのアミホスチン、組成物1mlあたり約100mgの製剤学的に許容 される賦形剤、および約12.5%(v/v)のエタノール水溶液を含有する組成物 を調製し、 (b)該組成物を室温から約−35℃へ約160分で冷却し、 (c)該組成物を約−35℃に約240分間維持して結晶質アミホスチンの種 結晶を形成させ、 (d)該組成物を約0℃へ約25分で温め、 (e)該組成物を約0℃で約600分間維持し、種結晶をアニールして結晶質 アミホスチンを沈殿させ、 (f)該組成物を約0℃から約−15℃へ約15分で冷却し、 (g)該組成物を約−15℃から約−35℃へ約120分で冷却し、 (h)該組成物を約−35℃で約180分間維持し、 (i)該組成物の周囲の空気を排気して約150ミクロン以下の圧力となし、 (j)該組成物を約−35℃から約−20℃へ約54時間かけて温め、 (k)該組成物を約−20℃で約12〜24時間維持して、安定性の向上した 結晶質アミホスチン組成物を残存させる、 各段階からなる方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92292992A | 1992-07-31 | 1992-07-31 | |
US922,929 | 1992-07-31 | ||
US08/099,298 US5424471A (en) | 1992-07-31 | 1993-07-29 | Crystalline amifostine compositions and methods of the preparation and use of same |
US099,298 | 1993-07-29 | ||
PCT/US1993/007222 WO1994003179A1 (en) | 1992-07-31 | 1993-07-30 | Crystalline amifostine compositions and methods for the preparation and use of same |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08500104A true JPH08500104A (ja) | 1996-01-09 |
JP3503943B2 JP3503943B2 (ja) | 2004-03-08 |
Family
ID=26795942
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50547994A Expired - Lifetime JP3503943B2 (ja) | 1992-07-31 | 1993-07-30 | 結晶質アミホスチン組成物及びその調製方法並びに使用 |
Country Status (23)
Country | Link |
---|---|
US (1) | US5591731A (ja) |
EP (1) | EP0655917B1 (ja) |
JP (1) | JP3503943B2 (ja) |
CN (2) | CN1070370C (ja) |
AT (1) | ATE261729T1 (ja) |
AU (1) | AU681858B2 (ja) |
CA (1) | CA2120133C (ja) |
CZ (1) | CZ284417B6 (ja) |
DE (1) | DE69333453T2 (ja) |
DK (1) | DK0655917T3 (ja) |
ES (1) | ES2215992T3 (ja) |
HK (1) | HK1010692A1 (ja) |
HU (1) | HU227122B1 (ja) |
IL (1) | IL106540A (ja) |
IS (1) | IS1843B (ja) |
MX (1) | MX9304627A (ja) |
NO (2) | NO309636B1 (ja) |
NZ (1) | NZ255182A (ja) |
PL (1) | PL178463B1 (ja) |
PT (1) | PT655917E (ja) |
RU (1) | RU2125880C1 (ja) |
SG (1) | SG47101A1 (ja) |
SK (1) | SK283318B6 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002529519A (ja) * | 1998-11-16 | 2002-09-10 | メドイミューン オンコロジー,インコーポレーテッド | 安定な非晶質アミフォスチン組成物およびその製造法および使用法 |
JP2015516465A (ja) * | 2011-06-03 | 2015-06-11 | タイワン ホパックス ケミカルズ マニュファクチャリング カンパニーリミテッド | 医薬組成物 |
JP2017530159A (ja) * | 2014-10-02 | 2017-10-12 | サイトソーベンツ・コーポレーション | 放射線で誘発された粘膜炎、食道炎、小腸炎、大腸炎、及び胃腸管急性放射線症候群を予防又は治療するための胃腸管投与多孔質消化管吸着剤ポリマーの使用 |
WO2024063285A1 (ko) * | 2022-09-23 | 2024-03-28 | 주식회사 경보제약 | 아비박탐 나트륨 염의 안정한 일수화물 형태 및 그의 제조 방법 |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6573253B2 (en) | 1997-02-12 | 2003-06-03 | Medimmune Oncology Inc. | Methods for the administration of amifostine and related compounds |
US6051563A (en) | 1997-02-12 | 2000-04-18 | U.S. Bioscience, Inc. | Methods for the administration of amifostine and related compounds |
US5994409A (en) * | 1997-12-09 | 1999-11-30 | U.S. Bioscience, Inc. | Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds |
US6239119B1 (en) | 1998-04-27 | 2001-05-29 | Medimmune Oncology, Inc. | Topical administration of amifostine and related compounds |
US6017922A (en) * | 1998-05-18 | 2000-01-25 | U.S. Bioscience, Inc. | Thermally stable trimetrexates and processes for producing the same |
US6384259B1 (en) | 1998-11-16 | 2002-05-07 | Medimmune Oncology, Inc. | Stable amorphous amifostine compositions and dosage form |
DE10043170C2 (de) * | 2000-09-01 | 2002-10-24 | Klinge Co Chem Pharm Fab | Amifostin-Monohydrat und Verfahren zu seiner Herstellung |
CN1148192C (zh) * | 2000-10-19 | 2004-05-05 | 南京振中生物工程有限公司 | 细胞保护剂氨磷汀制剂及其制备方法 |
US7053072B2 (en) | 2001-05-11 | 2006-05-30 | Medimmune Oncology, Inc. | Methods for the administration of amifostine and related compounds |
AU2003217676B2 (en) | 2002-02-22 | 2009-06-11 | Takeda Pharmaceutical Company Limited | Active agent delivery systems and methods for protecting and administering active agents |
US7629333B2 (en) * | 2002-03-29 | 2009-12-08 | Medimmune, Llc | Stable amorphous amifostine compositions and methods for the preparation and use of same |
CN1305478C (zh) * | 2004-05-12 | 2007-03-21 | 天津市资福医药科技开发有限公司 | 氨磷汀冻干制剂及其制备方法 |
NZ598441A (en) | 2005-02-16 | 2013-07-26 | Anacor Pharmaceuticals Inc | Boron-containing small molecules |
WO2007047315A1 (en) * | 2005-10-20 | 2007-04-26 | Albemarle Corporation | Amifostine dihydrate crystalline composition |
US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
BRPI0621279B1 (pt) | 2005-12-30 | 2021-07-20 | Anacor Pharmaceuticals, Inc | Moléculas pequenas contendo boro |
SI2719388T1 (sl) | 2006-02-16 | 2019-06-28 | Anacor Pharmaceuticals, Inc. | Majhne molekule, polnjene z borom, kot učinkovine proti vnetjem |
US9585849B2 (en) | 2006-04-17 | 2017-03-07 | The Burlington Hc Research Group, Inc. | Broad spectrum antiviral and methods of use |
EP2010166B1 (en) * | 2006-04-17 | 2013-11-06 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Organic disulfide antiretroviral agents |
WO2008060441A2 (en) * | 2006-11-09 | 2008-05-22 | Scidose Llc | Stable amifostine liquid concentrate |
EP3246034A1 (en) | 2008-03-06 | 2017-11-22 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as anti-inflammatory agents |
WO2009140309A2 (en) * | 2008-05-12 | 2009-11-19 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
CN101412732B (zh) * | 2008-09-02 | 2011-09-07 | 大连美罗药业股份有限公司 | 三水合3-氨基丙基胺乙基硫代磷酸高纯稳定晶体及其制备方法 |
CN101347412B (zh) * | 2008-09-02 | 2011-07-27 | 大连美罗药业股份有限公司 | 三水合氨磷汀结晶冻干制剂及其制备方法 |
EP2348863A4 (en) * | 2008-09-04 | 2012-03-07 | Anacor Pharmaceuticals Inc | BORN SMALL MOLECULES |
WO2010028005A1 (en) | 2008-09-04 | 2010-03-11 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
WO2010045503A1 (en) * | 2008-10-15 | 2010-04-22 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as anti-protozoal agents |
AU2009335744A1 (en) * | 2008-12-17 | 2010-07-15 | Anacor Pharmaceuticals, Inc. | Polymorphs of (S)-3-aminomethyl-7-(3-hydroxy-propoxy) -3H-benzo[c][1,2] oxaborol-1-ol |
AU2010281439A1 (en) * | 2009-07-28 | 2012-03-15 | Anacor Pharmaceuticals, Inc. | Trisubstituted boron-containing molecules |
AP4039A (en) * | 2009-08-14 | 2017-02-28 | Daitao Chen | Boron-containing small molecules as antiprotozoal agents |
MX2012002031A (es) * | 2009-08-19 | 2012-07-04 | Anacor Pharmaceuticals Inc | Moleculas pequeñas que contienen boro como agentes antiprotozoarios. |
WO2011037731A1 (en) * | 2009-09-25 | 2011-03-31 | Anacor Pharmaceuticals, Inc. | Boron containing small molecules |
WO2011049971A1 (en) | 2009-10-20 | 2011-04-28 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as antiprotozoal agents |
WO2011060199A1 (en) * | 2009-11-11 | 2011-05-19 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
EP2501234B1 (en) * | 2009-11-20 | 2017-09-13 | Tonix Pharma Holdings Limited | Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine |
WO2011094450A1 (en) | 2010-01-27 | 2011-08-04 | Anacor Pharmaceuticals, Inc | Boron-containing small molecules |
US8623911B2 (en) | 2010-03-19 | 2014-01-07 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as anti-protozoal agent |
US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
EP2613788B1 (en) | 2010-09-07 | 2017-06-21 | Anacor Pharmaceuticals, Inc. | Benzoxaborole derivatives for treating bacterial infections |
US11998516B2 (en) | 2011-03-07 | 2024-06-04 | Tonix Pharma Holdings Limited | Methods and compositions for treating depression using cyclobenzaprine |
CN102286020A (zh) * | 2011-07-11 | 2011-12-21 | 大连美罗大药厂 | 一水合3-氨基丙基胺乙基硫代磷酸的制备方法 |
EP2968992B8 (en) | 2013-03-15 | 2020-01-15 | Tonix Pharma Holdings Limited | Eutectic formulations of cyclobenzaprine hydrochloride and mannitol |
WO2014204854A1 (en) * | 2013-06-18 | 2014-12-24 | Aminomdix Inc. | Compositions and methods for the preparation of kidney protective agents comprising amifostine and amino acids |
CN107072968B (zh) | 2014-09-18 | 2021-01-12 | 通尼克斯制药控股有限公司 | 环苯扎林盐酸盐的低共熔混合物配制剂 |
US11447506B2 (en) | 2016-05-09 | 2022-09-20 | Anacor Pharmaceuticals, Inc. | Crystal forms of crisaborole in free form and preparation method and use thereof |
EP3723860A1 (en) | 2017-12-11 | 2020-10-21 | Tonix Pharma Holdings Limited | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions |
CN110606868A (zh) * | 2018-10-30 | 2019-12-24 | 中国科学院化学研究所 | 一种制备多肽或蛋白质单晶或无定型物的方法 |
CN110735177B (zh) * | 2018-10-30 | 2024-03-22 | 中国科学院化学研究所 | 一种利用溶液冻结制备单晶或无定型物的方法 |
WO2020088479A1 (zh) * | 2018-10-30 | 2020-05-07 | 中国科学院化学研究所 | 一种利用水溶液制备单晶或无定型物的方法 |
CN110735176B (zh) * | 2018-10-30 | 2024-03-22 | 中国科学院化学研究所 | 一种制备配位化合物单晶或无定型物的方法 |
WO2020088481A1 (zh) * | 2018-10-30 | 2020-05-07 | 中国科学院化学研究所 | 一种制备药物或药物中间体单晶或无定型物的方法 |
CN110607551B (zh) * | 2018-10-30 | 2024-02-20 | 中国科学院化学研究所 | 一种制备食品添加剂单晶或无定型物的方法 |
CN110616463B (zh) * | 2018-10-30 | 2024-03-22 | 中国科学院化学研究所 | 一种制备有机半导体分子单晶或无定型物的方法 |
EP3824880A1 (en) * | 2019-11-25 | 2021-05-26 | Clevexel Pharma | Freeze-dried powder containing 2-[(3-aminopropyl)amino]ethanethiol and its use for preparing a thermogel |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3892824A (en) * | 1968-12-16 | 1975-07-01 | Southern Res Inst | S-{107 -({107 -aminoalkylamino)alkyl dihydrogen phosphorothioates |
JPS6041676B2 (ja) * | 1977-09-21 | 1985-09-18 | 山之内製薬株式会社 | S−2−(3−アミノプロピルアミノ)エチルジハイドロジエンホスホロチオエ−ト1水和結晶の新規製法 |
US4424216A (en) * | 1979-07-31 | 1984-01-03 | The Rockefeller University | Method for the reduction of mucin viscosity |
DE3586845T2 (de) * | 1984-08-08 | 1993-04-01 | Survival Technology | Absorptionsverbesserer. |
JPH04505760A (ja) * | 1989-05-24 | 1992-10-08 | ユー・エス・バイオサイエンス | Aztの副作用および毒性からの保護方法 |
-
1993
- 1993-06-30 SG SG1996007320A patent/SG47101A1/en unknown
- 1993-07-30 ES ES93918552T patent/ES2215992T3/es not_active Expired - Lifetime
- 1993-07-30 PL PL93307298A patent/PL178463B1/pl unknown
- 1993-07-30 RU RU95105441A patent/RU2125880C1/ru active
- 1993-07-30 CA CA002120133A patent/CA2120133C/en not_active Expired - Lifetime
- 1993-07-30 DE DE69333453T patent/DE69333453T2/de not_active Expired - Lifetime
- 1993-07-30 AT AT93918552T patent/ATE261729T1/de active
- 1993-07-30 SK SK113-95A patent/SK283318B6/sk not_active IP Right Cessation
- 1993-07-30 IS IS4060A patent/IS1843B/is unknown
- 1993-07-30 JP JP50547994A patent/JP3503943B2/ja not_active Expired - Lifetime
- 1993-07-30 HU HU9500277A patent/HU227122B1/hu unknown
- 1993-07-30 IL IL10654093A patent/IL106540A/xx not_active IP Right Cessation
- 1993-07-30 PT PT93918552T patent/PT655917E/pt unknown
- 1993-07-30 AU AU47966/93A patent/AU681858B2/en not_active Expired
- 1993-07-30 MX MX9304627A patent/MX9304627A/es unknown
- 1993-07-30 EP EP93918552A patent/EP0655917B1/en not_active Expired - Lifetime
- 1993-07-30 NZ NZ255182A patent/NZ255182A/en not_active IP Right Cessation
- 1993-07-30 DK DK93918552T patent/DK0655917T3/da active
- 1993-07-30 CZ CZ95230A patent/CZ284417B6/cs not_active IP Right Cessation
- 1993-07-31 CN CN93117436A patent/CN1070370C/zh not_active Expired - Lifetime
-
1995
- 1995-01-30 NO NO950343A patent/NO309636B1/no not_active IP Right Cessation
- 1995-02-16 US US08/389,386 patent/US5591731A/en not_active Expired - Lifetime
-
1998
- 1998-10-29 HK HK98111596A patent/HK1010692A1/xx not_active IP Right Cessation
-
2000
- 2000-11-15 NO NO20005775A patent/NO315691B1/no not_active IP Right Cessation
- 2000-12-01 CN CNB00128097XA patent/CN1146428C/zh not_active Expired - Lifetime
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002529519A (ja) * | 1998-11-16 | 2002-09-10 | メドイミューン オンコロジー,インコーポレーテッド | 安定な非晶質アミフォスチン組成物およびその製造法および使用法 |
JP4703854B2 (ja) * | 1998-11-16 | 2011-06-15 | メディミューン,エルエルシー | 安定な非晶質アミフォスチン組成物およびその製造法および使用法 |
JP2015516465A (ja) * | 2011-06-03 | 2015-06-11 | タイワン ホパックス ケミカルズ マニュファクチャリング カンパニーリミテッド | 医薬組成物 |
JP2017530159A (ja) * | 2014-10-02 | 2017-10-12 | サイトソーベンツ・コーポレーション | 放射線で誘発された粘膜炎、食道炎、小腸炎、大腸炎、及び胃腸管急性放射線症候群を予防又は治療するための胃腸管投与多孔質消化管吸着剤ポリマーの使用 |
JP2020172528A (ja) * | 2014-10-02 | 2020-10-22 | サイトソーベンツ・コーポレーション | 放射線で誘発された粘膜炎、食道炎、小腸炎、大腸炎、及び胃腸管急性放射線症候群を予防又は治療するための胃腸管投与多孔質消化管吸着剤ポリマーの使用 |
WO2024063285A1 (ko) * | 2022-09-23 | 2024-03-28 | 주식회사 경보제약 | 아비박탐 나트륨 염의 안정한 일수화물 형태 및 그의 제조 방법 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08500104A (ja) | 結晶質アミホスチン組成物及びその調製方法並びに使用 | |
US5424471A (en) | Crystalline amifostine compositions and methods of the preparation and use of same | |
JP4703854B2 (ja) | 安定な非晶質アミフォスチン組成物およびその製造法および使用法 | |
JP3576180B2 (ja) | 改良イフォスファミド凍結乾燥組成物 | |
PT1687031E (pt) | Preparação farmacêutica contendo um anticorpo contra o receptor do egf | |
JP6542888B2 (ja) | カルムスチン医薬組成物 | |
JP6182262B2 (ja) | 抗がん剤を含む安定な水溶性医薬組成物 | |
JP2023116657A (ja) | 安定な滅菌性且つ結晶性o-アセチルサリチル酸(アスピリン)のバイアル内堆積物 | |
JP4142149B2 (ja) | バンコマイシンの凍結乾燥製剤 | |
JP2003514032A (ja) | 安定な非晶質アミフォスチン組成物およびその製造法 | |
WO2016005995A2 (en) | Glycol free stable liquid compositions of bendamustine | |
JP2011137048A (ja) | 新たな用途の薬学的調製物およびその調製物を製造するためのプロセス | |
US5972912A (en) | Method for lyophilizing ifosfamide | |
US20060089329A1 (en) | Ready-to-use gemcitabine solution concentrates | |
EP3856151B1 (en) | Lyophilisate of treosulfan | |
EP2968595A2 (en) | Voriconazole formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20031209 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081219 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091219 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091219 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101219 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101219 Year of fee payment: 7 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101219 Year of fee payment: 7 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111219 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121219 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121219 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131219 Year of fee payment: 10 |
|
EXPY | Cancellation because of completion of term |